跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MYLAN-NAPROXEN/ESOMEPRAZOLE MR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Authorized
STANDARD
MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Mylan Pharmaceuticals ULC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f96e4acdabf087d1
Company
Mylan Pharmaceuticals ULC
Type
Standard
Approval Details
Approval Id
f96e4acdabf087d1
Drug Approval Canada Name
MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Product Name
MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Status
Marketed
Status Date
2017-02-27
Original Market Date
2017-02-27
Din
02458608
Drug Class
Human
Dosage Form
Tablet (Immediate And Delayed-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:08.04.92
Atc Original
M01AE52 NAPROXEN AND ESOMEPRAZOLE
Atc Name
m 01 ae 52
Aig Number
0252870001
Company Name
Mylan Pharmaceuticals ULC
Company Address
85 Advance Road, Etobicoke, Ontario, Canada, M8Z 2S6
Active Ingredients
NAPROXEN
375 MG
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE)
20 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f96e4acdabf087d1
Type
Standard
Back to Health Canada Approvals